CD-008-0045

DRUG2 trials

Sponsors

ChemRar Research and Development Institute, LLC

Conditions

Anxiety Disorder Generalized

Phase 2

А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

CompletedNCT04524975

ChemRar Research and Development Institute, LLCAnxiety Disorder Generalized

Start: 2018-10-02End: 2019-11-01Updated: 2020-08-24

Phase 3

A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

ChemRar Research and Development Institute, LLCAnxiety Disorder Generalized

Start: 2020-12-31End: 2023-06-30Target: 200Updated: 2020-10-22